CRSP CRISPR Therapeutics 2026. Casgevy CRISPR therapy, BEAM NTLA BLUE competition, CAR-T pipeline, and commercialization scenarios for investors.
VKTX Viking Therapeutics 2026. VK2735 obesity Phase 3, oral GLP-1 race vs LLY NVO, VK0214 X-ALD pipeline, M&A optionality and clinical scenarios.
Madrigal Pharmaceuticals (MDGL) 2026 stock analysis: Rezdiffra revenue trajectory reaching $958M in FY2025 and $311M in Q1 2026, US payer coverage progress, GLP-1 competition dynamics, confirmatory trial risk, and acquisition thesis.
AstraZeneca (AZN) 2026 stock outlook covering Tagrisso, Enhertu, Datroway ADC pipeline, Farxiga CVRM growth, China VBP risk, and US Medicare price negotiation impact. Revenue data through Q1 2026.
NVO Novo Nordisk stock outlook for 2026. Wegovy and Ozempic franchise vs Eli Lilly competition, CagriSema REDEFINE trial setback, IRA Medicare drug pricing risk, amycretin pipeline, and three-scenario valuation analysis for US investors.